The Fund seeks to achieve long-term capital appreciation by investing primarily in equity securities of companies in any country outside of Canada and the United States.
Is this fund right for you?
- You want your money to grow over a longer term.
- You want to invest in companies outside of Canada and the U.S.
- You're comfortable with a medium level of risk.
Risk Rating
How is the fund invested?
(as of May 31, 2025)
Asset allocation (%)
|
Name |
Percent |
|
International Equity |
94.9 |
|
US Equity |
4.0 |
|
Cash and Equivalents |
1.1 |
Geographic allocation (%)
|
Name |
Percent |
|
France |
15.8 |
|
United Kingdom |
15.4 |
|
Japan |
14.6 |
|
Germany |
12.7 |
|
Sweden |
8.0 |
|
India |
6.0 |
|
Switzerland |
5.8 |
|
Taiwan |
4.7 |
|
United States |
4.0 |
|
Other |
13.0 |
Sector allocation (%)
|
Name |
Percent |
|
Industrial Goods |
19.0 |
|
Consumer Goods |
16.9 |
|
Financial Services |
16.3 |
|
Technology |
12.0 |
|
Healthcare |
10.4 |
|
Real Estate |
9.7 |
|
Basic Materials |
4.7 |
|
Industrial Services |
3.9 |
|
Consumer Services |
3.4 |
|
Other |
3.7 |
Growth of $10,000
(since inception)
Data not available based on date of inception
Fund details
(as of May 31, 2025)
Top holdings |
% |
HDFC Bank Ltd - ADR |
6.0 |
L'Air Liquide SA |
4.7 |
Sap SE |
4.7 |
Taiwan Semiconductor Manufactrg Co Ltd - ADR |
4.7 |
Deutsche Boerse AG Cl N |
4.3 |
Sony Group Corp |
4.1 |
Ferguson Enterprises Inc |
4.0 |
Relx PLC |
3.9 |
Siemens AG Cl N |
3.8 |
Nestle SA Cl N |
3.8 |
Total allocation in top holdings |
44.0 |
Portfolio characteristics |
|
Standard deviation |
12.6% |
Dividend yield |
1.8% |
Average market cap (million) |
$234,770.9 |
Understanding returns
Annual compound returns (%)
1 MO |
3 MO |
YTD |
1 YR |
{{snapShot.Return1Mth|customNumber:1}} | {{snapShot.Return3Mth|customNumber:1}} | {{snapShot.ReturnYTD|customNumber:1}} | {{snapShot.Return1Yr|customNumber:1}} |
3 YR |
5 YR |
10 YR |
INCEPTION |
{{snapShot.Return3Yr|customNumber:1}} | {{snapShot.Return5Yr|customNumber:1}} | {{snapShot.Return10Yr|customNumber:1}} | {{snapShot.ReturnInception|customNumber:1}} |
Calendar year returns (%)
2024 |
2023 |
2022 |
2021 |
{{snapShot.Return1YrCalendar|customNumber:1}} | {{snapShot.Return2YrCalendar|customNumber:1}} | {{snapShot.Return3YrCalendar|customNumber:1}} | {{snapShot.Return4YrCalendar|customNumber:1}} |
2020 |
2019 |
2018 |
2017 |
{{snapShot.Return5YrCalendar|customNumber:1}} | {{snapShot.Return6YrCalendar|customNumber:1}} | {{snapShot.Return7YrCalendar|customNumber:1}} | {{snapShot.Return8YrCalendar|customNumber:1}} |
Range of returns over five years
(November 1, 2018 - July 31, 2025)
Best return |
Best period end date |
Worst return |
Worst period end date |
12.5% |
Aug. 2024 |
9.1% |
July 2025 |
Average return |
% of periods with positive returns |
Number of positive periods |
Number of negative periods |
11.1% |
100.0% |
22 |
0 |
Q2 2025 Fund Commentary
Market commentary
International equities rose to new highs during the second quarter of 2025, but key risks remained. Global trade tensions, rising U.S. debt and weak U.S. gross domestic product growth continued to affect market sentiment. This was compounded by the threat of higher oil prices amid tensions in the Middle East.
Macroeconomic data pointed to rising recession risk, and June saw widespread downward revisions to growth forecasts. Trade policy uncertainty clouded the economic outlook, with tariff disruptions affecting inflation expectations and business investment. The European Central Bank made its eighth interest-rate cut, while the U.S. Federal Reserve Board kept interest rates steady.
Performance
The Fund’s relative exposure to Ferguson Enterprises Inc. and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) had the most positive impact on performance. Ferguson benefited from revenue growth and market share gains, raising its full-year 2025 outlook. TSMC’s May revenue was better than expected, up 40% year over year.
Relative exposure to AstraZeneca PLC was negative for performance. Its shares fell along with its peers when the U.S. administration announced plans to cut U.S. prescription drug costs.
At the sector level, stock selection in financials and information technology had the most positive impact on the Fund’s performance. Overweight exposure to industrials and information technology also had a positive impact. Security selection in industrials was negative for performance.
At a regional level, overweight exposure to India had a positive impact on performance. Overweight exposure to Sweden and underweight exposure to Japan had a negative impact.
Portfolio activity
The sub-advisor added Galderma Group AG, the world’s largest independent dermatology company, to the Fund. It operates in the fastest-growing segments of the dermatology market. The company has a strong track record of above-market growth, underpinned by long-term trends, premium brand positioning and high barriers to entry.
Daikin Industries Ltd. was sold in favour of buying Heidelberg Materials AG. Daikin’s stock performed well, but China’s real estate slump exposed the company’s profit reliance on the region. The sub-advisor believes Heidelberg Materials, a global supplier of heavy building materials, should benefit from European fiscal stimulus, tightening carbon regulations and margin improvement.
Outlook
Le fonds est constitué d’une combinaison équilibrée de sociétés affichant différents degrés de croissance. Le sous-conseiller privilégie les entreprises de croissance qui génèrent de bons niveaux de flux de trésorerie et présentent un bilan solide. Le sous-conseiller estime que ces caractéristiques sont importantes dans le contexte actuel de marché incertain, ainsi qu’à long terme.